Zymeworks (ZYME) Net Income towards Common Stockholders (2021 - 2026)
Zymeworks (ZYME) posted Net Income towards Common Stockholders of -$44.2 million for Q1 2026, down 7.17% sequentially from -$41.2 million in Q4 2025, and down 95.1% YoY from -$900.6 million in Q1 2025.
Zymeworks (ZYME) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Zymeworks has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$44.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 95.1% year-over-year to -$44.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.7 million (up 9.7% YoY) and the FY2025 annual result came in at -$81.1 million, up 33.88% from the prior year.
- Net Income towards Common Stockholders declined to -$44.2 million in Q1 2026 per ZYME's latest filing, from -$41.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $309.4 million in Q4 2022 and troughed at -$72.6 million in Q1 2022.
- A 5-year average of -$14.3 million and a median of -$29.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders jumped 890.33% in 2022, then plunged 104.68% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at $309.4 million in 2022, then slumped by 104.68% to -$14.5 million in 2023, then tumbled by 62.31% to -$23.5 million in 2024, then slumped by 75.31% to -$41.2 million in 2025, then decreased by 7.17% to -$44.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$44.2 million, -$41.2 million, and -$19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -45.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.02 Mn |
| Mar 31, 2026 | -44.16 Mn |
| Dec 31, 2025 | -41.21 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -23.51 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -31.65 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -28.69 Mn |
| Jun 30, 2023 | -51.15 Mn |
| Mar 31, 2023 | -24.35 Mn |
| Dec 31, 2022 | 309.43 Mn |
| Sep 30, 2022 | -47.85 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | -39.15 Mn |
| Sep 30, 2021 | -60.58 Mn |